ARTICLE
7 May 2024

LDT Oversight Gets Long-Awaited FDA Final Rule

M
Mintz

Contributor

Mintz is a litigation powerhouse and business accelerator serving leaders in life sciences, private equity, sustainable energy, and technology. The world’s most innovative companies trust Mintz to provide expert advice, protect and monetize their IP, negotiate deals, source financing, and solve complex legal challenges. The firm has over 600 attorneys across offices in Boston, Los Angeles, Miami, New York, Washington, DC, San Francisco, San Diego, and Toronto.
Of Counsel Benjamin Zegarelli spoke with MD+DI on the FDA's updated regulations to classifying laboratory-developed tests (LDTs) as medical devices under the Federal Food, Drug, and Cosmetic Act...
United States Food, Drugs, Healthcare, Life Sciences

Of Counsel Benjamin Zegarelli spoke with MD+DI on the FDA's updated regulations to classifying laboratory-developed tests (LDTs) as medical devices under the Federal Food, Drug, and Cosmetic Act (FD&C Act).

Benjamin said, "Many LDT developers will become subject to FDA regulations that are already applicable to other medical devices, including other in vitro diagnostic devices, such as requirements to register manufacturing facilities and list commercial devices with FDA, applying compliant labeling to commercial devices, reporting certain device adverse events and malfunctions, and implementing a compliant quality system."

SOURCE

MD+DI

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More